Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...

The cuts at two Massachusetts plants follow further site closures and layoffs across the company over the past few years.

They engineered an adenoviral vector to include a repressor protein ... other advantages over alternative ‘helper-free’ rAAV manufacturing systems. “For all the serotypes tested, we ...